Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
出版年份 2020 全文链接
标题
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
作者
关键词
Favipiravir, SARS-CoV-2, COVID-19, Coronavirus, Antiviral, Randomized clinical trial
出版物
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 103, Issue -, Pages 62-71
出版商
Elsevier BV
发表日期
2020-11-17
DOI
10.1016/j.ijid.2020.11.142
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
- (2020) Kaijin Xu et al. CLINICAL INFECTIOUS DISEASES
- Risk Factors for Viral RNA Shedding in COVID-19 Patients
- (2020) Yu Fu et al. EUROPEAN RESPIRATORY JOURNAL
- Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: A retrospective cohort study
- (2020) Lin Qi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- SARS-CoV-2 RNA polymerase as target for antiviral therapy
- (2020) Luigi Buonaguro et al. Journal of Translational Medicine
- COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
- (2020) Yang Song et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19
- (2020) Anália Carmo et al. JOURNAL OF MEDICAL VIROLOGY
- An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2
- (2020) Joshua T Schiffer et al. Open Forum Infectious Diseases
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response
- (2020) Ashish Goyal et al. Science Advances
- Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
- (2018) Leen Delang et al. ANTIVIRAL RESEARCH
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
- (2016) Carl J Heneghan et al. HEALTH TECHNOLOGY ASSESSMENT
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now